MedTrace Logo

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

NCT00584402 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver.

Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography

Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

Conditions

  • Liver Neoplasms

Interventions

DRUG

perflutren lipid microspheres

perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • John P. McGahan, M.D. · UC Davis School of Medicine Dept. of Radiology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584402 on ClinicalTrials.gov